AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently conducting a Phase IIb study titled ‘A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids.’ The study aims to evaluate the efficacy and safety of the drug Tozorakimab in adults with uncontrolled asthma who are already on medium-to-high dose inhaled corticosteroids. This research is significant as it seeks to provide a new treatment option for asthma patients who do not respond adequately to existing therapies.
The intervention being tested is Tozorakimab, administered subcutaneously. It is being compared against a placebo to determine its effectiveness in managing asthma symptoms.
The study is interventional with a randomized, parallel assignment model. It involves three groups: two experimental groups receiving different doses of Tozorakimab and one placebo group. The study employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on March 26, 2025, with the primary completion date yet to be announced. The last update was submitted on July 15, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, especially if Tozorakimab proves effective. Success in this study might position AstraZeneca favorably against competitors in the respiratory treatment market, potentially leading to increased market share.
The study is ongoing, with further details available on the ClinicalTrials portal.